文献速递心脏核医学

心率与血压对瑞加诺生负荷试验的反应的预后价值

The prognostic utility of heart rate and blood pressure response to regadenoson stress.
PubMed 文献 · J Nucl Cardiol · 2024-10-04

回顾性队列纳入10227例接受瑞加诺生负荷单光子发射计算机断层心肌灌注显像(MPI)的患者,计算心率反应(HRR)与收缩压反应(SBPR)。随访35±21个月期间921例(8.8%)死亡;HRR与SBPR均与全因死亡独立相关,HRR提供增量预后价值而SBPR不提供。

要点

  • HRR中位数35%(IQR 21%–51%),SBPR中位数-9%(IQR -17%–-2%)。
  • HRR每增加1%调整HR为0.980(CI 0.977–0.984),SBPR每增加1%调整HR为0.994(CI 0.988–0.999)。
  • HRR<20%可作为改善风险分层的切点,HRR提供增量预后价值而SBPR不提供。

核心结论

  • 在接受负荷MPI的患者中,瑞加诺生负荷后HRR受损对全因死亡提供独立且增量的预后价值,优于临床、影像及SBPR数据。
  • SBPR与HRR正相关,但不提供增量预后效用。
  • 作者认为应常规报告HRR而非SBPR,并将其纳入患者整体风险评估;HRR异常阈值<20%可改善风险分层。

研究设计与样本

  • 回顾性队列研究,纳入10227例接受瑞加诺生负荷单光子发射计算机断层心肌灌注显像(MPI)的患者。
  • HRR与SBPR均按100×(充血峰值-基线值)/基线值计算。
  • 随访35±21个月。

主要发现

  • 随访期间观察到921例(8.8%)死亡。
  • HRR中位数35%(IQR 21%–51%),SBPR中位数-9%(IQR -17%–-2%)。
  • HRR每增加1%的调整HR为0.980(CI 0.977–0.984),SBPR每增加1%的调整HR为0.994(CI 0.988–0.999)。
  • 死亡率随HRR四分位数降低和SBPR三分位数降低而升高。
  • HRR在临床与影像参数之上提供增量预后价值(AUC增加0.03;P<.001),在SBPR数据之上亦提供增量预后价值(AUC增加0.11;P<.0001);SBPR在临床与影像参数或HRR数据之上未提供显著增量预后价值。

关键数值与推荐

  • HRR<20%为推导并验证的切点,可在临床与MPI所见之外改善风险分层。
  • HRR每增加1%调整HR为0.980(CI 0.977–0.984),SBPR每增加1%调整HR为0.994(CI 0.988–0.999)。
  • HRR在临床与影像参数之上AUC增加0.03(P<.001),在SBPR数据之上AUC增加0.11(P<.0001)。

临床怎么用

  • 作者认为应常规报告HRR而非SBPR,并在评估患者整体风险时考虑HRR。
  • 作者认为HRR异常阈值<20%可改善风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although heart rate response (HRR) to regadenoson stress has been shown to be a strong predictor of outcome, it has not been investigated in a large all-comers cohort. The prognostic utility of systolic blood pressure response (SBPR) has not been investigated in comparison with HRR. METHODS AND RESULTS: In a retrospective cohort of 10,227 patients undergoing regadenoson stress single-photon emission computed tomography myocardial perfusion imaging (MPI), HRR, and SBPR were calculated as 100×(peak hyperemia value-baseline value)/baseline value. During 35±21 months follow-up, 921 (8.8%) deaths were observed. The median HRR was 35% (interquartile range [IQR], 21% to 51%). The median SBPR was -9% (IQR, -17% to -2%). HRR and SBPR were independently associated with all-cause mortality with adjusted hazard ratio [HR] of .980 per 1% increment in HRR (CI, .977-.984) and .994 per 1% increment in SBPR (CI, .988-.999). Mortality rates increased with decreasing HRR quartile and SBPR tertile. HRR provided incremental prognostic value for all-cause mortality beyond clinical and imaging parameters (area under the curve [AUC] increase, .03; P<.001) and SBPR data (AUC increase, .11; P<0001). SBPR did not provide significant incremental prognostic value beyond clinical and imaging parameters or HRR data. We derived and validated HRR of <20% as a cut-off that can improve risk stratification beyond clinical and MPI findings. CONCLUSION: Among patients undergoing stress MPI, impaired HRR to regadenoson provided independent and incremental prognostic value for all-cause mortality beyond clinical, imaging, and SBPR data. SBPR positively correlates with HRR, but it does not provide incremental prognostic utility. HRR, but not SBPR, should be routinely reported and considered in assessing patients' overall risk. An abnormal HRR threshold of <20% can improve risk stratification.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Torres A, Yerkan A, Abbasi A, et al. The prognostic utility of heart rate and blood pressure response to regadenoson stress. J Nucl Cardiol. 2024. PMID: 39368660. doi:10.1016/j.nuclcard.2024.102050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。